Ovarian cancer: Current status and strategies for improving therapeutic outcomes

A Chandra, C Pius, M Nabeel, M Nair… - Cancer …, 2019 - Wiley Online Library
Of all the gynecologic tumors, ovarian cancer (OC) is known to be the deadliest. Advanced‐
stages of OC are linked with high morbidity and low survival rates despite the immense …

MET oncogene in non-small cell lung cancer: mechanism of MET dysregulation and agents targeting the HGF/c-Met axis

H Liang, M Wang - OncoTargets and therapy, 2020 - Taylor & Francis
Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related death worldwide
and has a poor prognosis. Current treatments for advanced NSCLC included traditional …

New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing

JS Ross, K Wang, L Gay, R Al-Rohil, JV Rand… - The …, 2014 - academic.oup.com
Background. Intrahepatic cholangiocarcinoma (ICC) is a subtype of primary liver cancer that
is rarely curable by surgery and is rapidly increasing in incidence. Relapsed ICC has a poor …

[HTML][HTML] EGFR-TKI resistance in NSCLC patients: mechanisms and strategies

Y Lin, X Wang, H Jin - American journal of cancer research, 2014 - ncbi.nlm.nih.gov
The epidermal growth factor receptor (EGFR) is a kind of receptor tyrosine kinase (RTK) that
plays a critical role in the initiation and development of malignant tumors via modulating …

The emerging role of MET/HGF inhibitors in oncology

GV Scagliotti, S Novello, J von Pawel - Cancer treatment reviews, 2013 - Elsevier
Abstract The N-methyl-N′-nitroso-guanidine human osteosarcoma transforming gene
(MET) receptor tyrosine kinase and its ligand hepatocyte growth factor (HGF) control cellular …

Cholangiocarcinoma

M Squadroni, L Tondulli, G Gatta, S Mosconi… - Critical reviews in …, 2017 - Elsevier
Biliary tract cancer accounts for< 1% of all cancers and affects chiefly an elderly population,
with predominance in men. We distinguish cholangiocarcinoma (intrahepatic, hilar and …

Emerging molecular therapeutic targets for cholangiocarcinoma

SI Ilyas, GJ Gores - Journal of hepatology, 2017 - Elsevier
Cholangiocarcinomas (CCAs) are diverse epithelial tumors arising from the liver or large
bile ducts with features of cholangiocyte differentiation. CCAs are classified anatomically …

Medical treatment for cholangiocarcinoma

J Adeva, B Sangro, M Salati, J Edeline… - Liver …, 2019 - Wiley Online Library
Most of the patients with cholangiocarcinoma (CCA) present with advanced (inoperable or
metastatic) disease, and relapse rates are high in those undergoing potentially curative …

MET signaling regulates glioblastoma stem cells

KM Joo, J Jin, E Kim, K Ho Kim, Y Kim, B Gu Kang… - Cancer research, 2012 - AACR
Glioblastomas multiforme (GBM) contain highly tumorigenic, self-renewing populations of
stem/initiating cells [glioblastoma stem cells (GSC)] that contribute to tumor propagation and …

Cholangiocarcinoma: molecular pathways and therapeutic opportunities

SI Ilyas, MJ Borad, T Patel… - Seminars in liver disease, 2014 - thieme-connect.com
Cholangiocarcinoma (CCA) is an aggressive biliary tract malignancy with limited treatment
options and low survival rates. Currently, there are no curative medical therapies for CCA …